 |
|
Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors
Basic Trial Information
Trial Description
Summary
Eligibility Criteria
Trial Contact Information
Basic Trial Information
| Phase | Type | Status | Age | Protocol IDs |
|---|
| Phase III, Phase II | Treatment | Active | 18 and over | 06-2247
NCT00442533 |
Trial Description
Summary The purpose of this study is to determine if High-dose 111In-Pentetreotide known as NeuroendoMedix®, is an effective treatment for Neuroendocrine Tumors. Eligibility Criteria Inclusion Criteria: - Patients must have received first line standard chemotherapy and/or radiation therapy for neuroendocrine malignancy in the past and failed the therapy.
- Patients must have evidence of residual multifocal active tumor.
- All patients must sign an informed consent indicating the awareness of the investigational nature of the studies involved.
- All patients must have a Karnofsky performance status of at least 60.
- Patients must be greater than 18 years of age.
- Patients must have measurable and/or followable disease based on either clinical or radiologic exam.
- Sensitivity to Indium-111 pentetreotide or any of its components is an absolute contraindication to participation in this trial.
- An absolute contraindication is pregnancy as evidenced by the clinical condition, a positive pregnancy test (B-HCG or pelvic ultrasound).
- If patients have received prior radionuclide therapy of the same product, there must be documented response to that therapy and/or residual active stable disease.
Exclusion Criteria: - Karnofsky performance status of 50 or less.
- Patients who are unable to give informed consent.
- Patients under 18 years of age. There will be no upper age discrimination.
- Patients who are pregnant or those potentially pregnant subjects not willing to practice effective contraceptive techniques during the study period.
- Patients with renal insufficiency as defined by a calculated creatinine clearance (based on age, weight and serum creatinine) of 39.9 ml/min or less.
Trial Contact Information
Trial Lead Organizations/Sponsors Radio Isotope Therapy of America Excel Diagnostic Imaging Clinics - Westchase District
RadioMedix, Incorporated
St. Luke's Texas Cancer Institute at St. Luke's Episcopal Hospital
| Ebrahim Delpassand, M.D. | | Principal Investigator |
Trial Sites
|
|
|
|
| U.S.A. |
|
| Texas |
|
| |
Houston |
|
| | | | | | | | | Excel Diagnostic Imaging Clinics - Westchase District |
| | | St. Luke's Texas Cancer Institute at St. Luke's Episcopal Hospital |
|
Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00442533
Information obtained from ClinicalTrials.gov on March 18, 2009 Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain
the same text. Minor
changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and
contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should
be directed to ClinicalTrials.gov.
Back to Top |
|
